The large CANTOS trial has recently shown that in adult CKD patients—in contrast to patients without CKD—already treated with statins, markers of inflammation (hsCRP, IL-6), but not lipid levels, were predictive of major adverse cardiovascular events, suggesting the need for additional anti-inflammatory therapeutic options [48]. Here, IL6 is linked to chronic kidney disease.